An interventional trial comparing ferumoxytol and gadolinium for estimating the immune cell content in brain tumours.

Not Applicable

• Conditions: Stage 3 and 4 astrocytoma; brain tumour metastasis; Cancer - Brain

• Registration Number: ACTRN12622000218796
• Lead Sponsor: Tania Slatter

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-02-07
• Last Update Posted: 21 February 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1.Patients with an imaging diagnosis based on the baseline diagnostic MRI scan (gadolinium contrast) of primary stage 3 or 4 astrocytoma, or brain tumour metastasis.
2.No steroid treatment that has been administered to the patients between the time of the baseline diagnostic scan and the ferumoxytol infusion.

Exclusion Criteria

1.Patients who are younger than 18 years old.
2.Patients who are pregnant or breast feeding.
3.Patients who have known allergy to iron preparations or other medication allergies.
4.Patients who have haemochromatosis or known clinically significant liver function abnormalities.
5.The initial diagnostic MRI demonstrates intracranial haemorrhage, calcification or other susceptibility blooming artifacts.

Study & Design

• Study Type: Interventional
• Study Design: Not specified